Breast cancer is the first leading cause of cancer mortality in women worldwide. Every year, above 1.3 million women are diagnosed with breast cancer and nearly 450,000 women die from it[@b1]. Metastasis, a process that cancer cells invade surrounding tissues and migrate to distal organs including lung, liver, brain, bone, and lymph nodes, is a major cause of mortality in breast cancer patients[@b2]. Therefore, development of safe and effective cancer metastasis chemopreventive agents is becoming important and badly needed. Metapristone, the most predominant biological active metabolite of mifepristone (RU486), is being developed as a novel cancer metastasis chemopreventive by us[@b3][@b4].

Metapristone has received considerable attention to its anticancer activity recently. In our previous studies, we showed that metapristone produced comparable antitumor effect on several cancer cell lines. For example, metapristone induced HT-29 cells to be arrested at the G0/G1 stage, induced dose-dependent apoptosis, and interfered with adhesion of HT-29 cells to human umbilical vein endothelial cells (HUVECs) *in vitro*[@b3][@b4][@b5].

Although the anticancer activity of metapristone has been exploited, its exact molecular mechanisms of actions and related pathways and targets towards cancer remain poorly understood. To get a more comprehensive understanding of metapristone functions on cancer, we employed the pharmacoproteomic analysis in the present study as we pioneered ten years ago[@b6]. Isobaric tags for relative and absolute quantitation (iTRAQ) technique is considered one of the most robust techniques for differential quantitative proteomic analysis[@b7], which yields very small coefficients of variation in quantitative measurements[@b8]. Unlike gel-based proteomic method, iTRAQ exhibits much better sensitivity and allows the identification and accurate quantification of proteins from multiple samples[@b9].

The epithelial--mesenchymal transition (EMT) is an important cellular process during which epithelial polarized cells become motile mesenchymal-appeared cells, which, in turn, promotes cancer cell invasion and metastasis[@b10][@b11]. The EMT process is very complex and controlled by various families of transcriptional regulators through different signaling pathways, including TGF-β, Wnt, MAPK, EGFR, PI3K and others[@b12][@b13][@b14]. Therefore, preventing cancer cells from epithelial-mesenchymal transition as well as intervening with the key proteins in EMT-related pathways is the main research objective for us to identify safe and effective cancer metastasis chemopreventives.

In the current study, we investigated the cancer metastasis chemopreventive effect of metapristone on the cell growth, migration, invasion and adhesion of MDA-MB-231 cells in *vitro*, and further explored the underlying molecular mechanism of metapristone by using an isobaric tag for relative and absolute quantitation iTRAQ combined with the tandem mass spectrometry (LC-ESI-MS/MS). We further identified differentially expressed proteins and potential signaling pathways in MDA-MB-231 cells after metapristone treatment. The findings reported in this study support our hypothesis and reveal, for the first time, a novel function for metapristone in the prevention of metastasis of breast cancer by intervening EMT-related signaling pathways.

Results
=======

Effect of metapristone on cell viability
----------------------------------------

To explore the metastasis chempreventives function of metapristone, the cytostatic effect was examined first on human breast cancer cells MDA-MB-231 after treatment with various concentrations of metapristone for 24 h. As showed in [Fig. 1A](#f1){ref-type="fig"}, the cytotoxicity of metapristone was low. The IC~50~ value for metapristone to suppress MDA-MB-231 cell proliferation is 91 μM.

Metapristone inhibits cell migration, adhesion, and invasion
------------------------------------------------------------

Would healing assay was conducted with MDA-MB-231 cells to examine the effect of metapristone on cell motility. As shown in [Fig. 1B](#f1){ref-type="fig"}, cellular migration was controlled in a concentration-dependent manner by metapristone, being inhibited by up to 15%, 23% and 43% at 10, 50 and 75 μM, respectively (*P* \< 0.01). Metapristone inhibited cell motility and wound closure at concentrations lower than its IC~50~, suggesting its specific inhibition on cell migration.

Tumor cells adhesion to the ECM is a fundamental step in cancer metastasis, the adherence of MDA-MB-231 cells to HUVECs was assessed to determine whether metapristone can regulate cell adhesion at a non-cytotoxic concentration. Ten fields of each well were randomly selected, and the adhered spots were counted. Compared with the control, the adhesion rate of MDA-MB-231 cells was 84, 68 and 39%, respectively, at 10, 50 and 75 μM of metapristone ([Fig. 1C](#f1){ref-type="fig"}). Metapristone markedly and in a concentration-dependent manner inhibited the adherence of MDA-MB-231 cells to endothelial monolayers, indicating that it may fit into a new class of therapy for the reduction of risk factors of cancer metastasis.

It is well known that MDA-MB-231 cells have strong invasion properties in matrigel. In this study, we investigate the inhibitory effect of metapristone on cell invasion using a transwell system coated with matrigel. We found that treatment with metapristone for 24 h significantly inhibited MDA-MB-231 cells invasion through the transwell membrane. When metapristone was added at 10, 50 and 75 μM, the inhibitory effects were much more obvious compared to that of untreated group, with the inhibition rate of 48.52%, 60.06% and 82.88%, respectively ([Fig. 1D](#f1){ref-type="fig"}).

Overview of quantitative proteomics
-----------------------------------

The iTRAQ analysis was performed on the purified protein extracts from MDA-MB-231 cells with or without metapristone treatment to understand the mechanism of metapristone-mediated anti-metastasis mechanism on the cellular and molecular level ([Fig. 2](#f2){ref-type="fig"}). In total, 440,119 spectra were obtained from the iTRAQ-LC-MS/MS proteomic analysis. After data filtering to eliminate low-scoring spectra, a total of 93,114 unique spectra that met the strict confidence criteria for identification were matched to 5,145 unique proteins, of which, 311 proteins showed significant differences in metapristone-treated cells (*P*-value \< 0.05). The detailed information including protein accession number, identified peptide number, protein score, sequence coverage, and regulation (fold change) for these identified proteins is shown in [Table 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}. Among these differentially expressed proteins (DEPs), 163 proteins were up-regulated ([Table 1](#t1){ref-type="table"}) and 148 proteins were down-regulated ([Table 2](#t2){ref-type="table"}). Then, GO analysis was conducted with the GSEABase package from R (<http://www.r-project.org/>) statistical platform[@b15]. Genes were classified in three major groups: the biological process, cellular component, and molecular function ([Fig. 3A--C](#f3){ref-type="fig"}). Approximately 50.94% of the altered proteins were binding proteins, 27.52% were catalytic and 3.91% were enzyme regulators. In addition, we performed COG function prediction and classified these 311 positive proteins into 18 functional categories ([Fig. 4](#f4){ref-type="fig"}).

KEGG pathway analysis was also performed based on the 311 DEPs. A total of 249 metapristone-related pathways were identified, which were assigned into 33 statistically remarkable categories (*P* value \< 0.01) ([Table 3](#t3){ref-type="table"}), including metabolic (such as "NADH dehydrogenase", P56181-2), Oxidative phosphorylation (such as "ATP synthase", O75947), MAPK signaling pathway (such as "Rac GTPase activating protein 1", B2RE34), Wnt signaling pathway (such as "RhoA", P61586), Focal adhesion (such as "Integrin alpha-2", P17301), ECM-receptor interaction (such as "Dystroglycan", Q14118), VEGF signaling pathway (such as "Protein kinase C", Q2TSD3), and TGF-beta signaling pathway (such as "TGF-beta receptor type-2", P37173-2).

Western blot validation of the proteomics analysis
--------------------------------------------------

Following the database search and classification of proteins, many differentially expressed proteins were reported to be involved in epithelial-to-mesenchymal transition (EMT), such as E-cadherin, vimentin, syndecan-1, β-catenin, dystroglycan, Smad2/3, glutaredoxin, TGF-β receptor, and so on. Western blots were performed on some selected proteins (E-cadherin, vimentin, β-catenin, and Smad 2) to further verify the iTRAQ results ([Fig. 5B,C](#f5){ref-type="fig"}). While vimentin, one mesenchymal cell marker, was down-regulated by metapristone treatment, E-cadherin, one epithelial cell marker, strengthened with the increasing concentration of metapristone. Moreover, the expression of phosphorylation of Smad 2 was also found to be decreased by metapristone treatment. Notably, the western blot images correlated very well and thus confirmed the iTRAQ data obtained.

Metapristone impedes EMT in MDA-MB-231cells *in vitro*
------------------------------------------------------

Epithelial to mesenchymal transition (EMT) and extracellular matrix degradation are critical for the initiation and progression of tumor invasion. As shown in [Fig. 5A](#f5){ref-type="fig"}, MDA-MB-231 cells initially exhibited a typical mesenchymal-like morphology with long and narrow stretch, while cells under the treatment of metapristone showed epithelial-like morphology with relatively round extension on the plastic surface. Furthermore, we sought to determine whether metapristone could inhibit Epithelial-mesenchymal transition by regulating EMT-related markers, such as vimentin (mesenchymal-specific marker) and E-cadherin (epithelial-specific marker). As shown in [Fig. 5D](#f5){ref-type="fig"}, up-regulated E-cadherin accumulated in the cell to cell junctions after metapristone treatment. Accordingly, the significantly reduced expression of the mesenchymal-specific marker vimentin was observed in the presence of metapristone.

Discussion
==========

Breast cancer metastasis accounts for the lethality of the disease and therefore there is an urgent need to develop new chemopreventives to inhibit cancer cell metastasis[@b16][@b17]. Experimental, epidemiological, and clinical data from the last three decades have each supported the hypothesis that oral contraceptive, such as mifepristone, possesses anticancer properties[@b18][@b19]. Then metapristone, the most predominant biological active metabolite of mifepristone, is being developed as a novel cancer metastasis chemopreventive agent by us.

Metastasis is a hallmark of cancer and the leading cause of mortality among cancer patients. The first step in metastasis is the migration of cancer cells away from the primary tumor, a process called tumor invasion[@b20]. Therefore, much research effortin recent years has been directed toward disruption of this step of the metastatic process[@b21][@b22]. In this study, we chose MDA-MB-231 cells with high metastatic potential to explore the effects of metapristone on the metastatic activity of human breast cancer cells. We showed that metapristone markedly inhibited their migratory ([Fig. 1B](#f1){ref-type="fig"}) and invasive ([Fig. 1D](#f1){ref-type="fig"}) abilities of MDA-MB-231 cells at low concentrations. Adhesion of cancer cells to ECM or vascular endothelium is also a crucial starting point of metastasis[@b23]. Here, we also found that metapristone markedly and in a concentration-dependent manner inhibited the adherence of MDA-MB-231 cells to endothelial monolayers. Collectively, these results suggested that metapristone had the ability to inhibit breast cancer cells metastasis. However, the underlying mechanism remains elusive.

Pharmacoproteomic, especially quantitative pharmacoproteomics, has been emerging as a powerful tool in cancer research, providing a unique avenue to investigate direct drug targets at a functional level[@b24][@b25]. Here, we have demonstrated the ability of the isobaric tags to detect and quantify differences in expression levels of proteins between metapristone-treated and untreated MDA-MB-231 cells that reflect functions associated with cancer cells metastasis. Temporal iTRAQ analysis identified 311 proteins as differentially expressed, with 163 as up-regulated ([Table 1](#t1){ref-type="table"}) and 148 as down-regulated ([Table 2](#t2){ref-type="table"}). Followed by GO analysis and KEGG pathway analysis, we established their potentially functional classification for the first time: there are 249 pathways, including metabolic, oxidative phosphorylation, p53, MAPK, Wnt, focal adhesion, VEGF, TGF-beta signaling pathways and so on ([Table 3](#t3){ref-type="table"}). Importantly, some of these pathways were reported to be linked to epithelial-to-mesenchymal transition (EMT) process, which was related with cancer carcinogenesis, prognosis and especially metastasis[@b14][@b26].

The epithelial-to-mesenchymal transition (EMT) has been considered as the initiation process of cancer metastasis, when non-invasive and non-metastatic tumor cells lose their epithelial phenotype, acquire invasive properties, infiltrate surrounding tissues and metastasize to secondary sites[@b27][@b28].Turning an epithelial cell into a mesenchymal cell requires loss of epithelial polarity, alteration in cellular architecture and acquisition of migrationcapacity[@b29]. It has also been described that during EMT, the epithelial cells acquire mesenchymal morphology, hence the expression of epithelial markers decreases and the expression of mesenchymal markers increases[@b30][@b31]. Here, we found that MDA-MB-231 cells initially exhibited a typical mesenchymal-like morphology with long and narrow stretch, while under the treatment of metapristone, cells showed epithelial-like morphology with relatively round extension on the plastic surface ([Fig. 5A](#f5){ref-type="fig"}). We also found that metapristone-treatment resulted in decreased expression of mesenchymal marker "vimentin" and increased expression of epithelial marker "E-cadherin" in MDA-MB-231. Vimentin is a well-known metastasis marker and therapeutic target, as inhibiting vimentin function reduces the ability of cells to migrate[@b32]. Some anti-cancer drugs that are currently used in the clinic directly target vimentin such as "silibinin"[@b33] and "withaferin A"[@b34]. One of the hallmarks of EMT is the functional loss of E-cadherin, which is thought to be a metastatic suppressor during tumor progression[@b35]. E-cadherin, encoded by the gene CDH1, is a transmembrane glycoprotein responsible for calcium-dependent cell-to-cell adhesion. E-cadherin plays a pivotal role in cadherin-catenin-cytoskeleton complexes, and it grants anti-invasive and anti-migratory properties to epithelial cells[@b36][@b37]. Our results suggest that metapristone inhibits cell migration, adhesion and invasion in highly metastatic human breast cancer cells, maybe in part, through the regulation of significant EMT-related markers which then leads to reversal of EMT.

Epithelial-to-mesenchymal transition, the process closely related to tumor development, is often regulated by a variety of signaling pathways and cytokines[@b12][@b13][@b14][@b26]. In this work, we performed KEGG pathway analysis based on the differential expressed proteins in MDA-MB-231 cells under metapristone-treated and untreated. We found some DEPs, including TGF β receptor I/II, Smad 2/3, RhoA, and Glutaredoxin, were related with Transforming Growth Factor β (TGF β) signaling pathway. TGF β signaling pathway has been characterized as an important inducer of EMT via several downstream signaling moleculars[@b13]. TGF β signals via formation of a heterotetrameric complex of TGF β receptor I/II (TGF β RI/RII), in which the active TGF β RII phosphorylates and activates the TGF β RI at the plasma membrane[@b38][@b39]. This conformational switch allows activated TGF β RI to interact with Smad2/3 through their MH2 domain. The activated type I receptor then propagates the signal to the nucleus by phosphorylating Smad 2 and Smad 3. Then, Smad2/3 can directly or indirectly regulate gene expression by controlling epigenetic processes, such as chromatin remodeling or by maintaining promoter DNA methylation, which is critical in silencing epithelial gene expression in cells that have undergone EMT[@b40]. Meanwhile, there exists a non-Smad pathway induced by TGF β[@b41]. In this non-Smad pathway, TGF β RII phosphorylates PAR6 (partitioning-defective protein 6), then inactivates the epithelial polarity complex, as well as activating of the small GTPase RhoA, which is contribute to cell invasion leading to breast cancer metastasis[@b42]. Furthermore, glutaredoxin (Grx), an anti-oxidant enzyme, was reported to play an important role in intervening TGF β-induced EMT process by reducing ROS generation in intracellular and suppressing the expression of mesenchymal markers[@b43]. Our results demonstrated that metapristone significantly inhibited the protein expression levels of TGF β RI/RII, RhoA, Smad 2/3, and up-regulated the expression level of glutaredoxin, implying that metapristone maybe in part, reverse EMT through attenuating TGFβ signaling pathway in MDA-MB-231 cells.

In addition to the TGF β signaling pathway, the Wnt signaling pathway also plays an important role in EMT[@b44][@b45]. Wnt pathway contributes to EMT by activating β-catenin, and then activating Snail, which in turn suppresses epithelial markers expression like E-cadherin[@b45][@b46]. Meanwhile, Caveolin-1 (CAV1), the principal structural protein of the cholesterol-rich plasma membrane invaginations, could induce EMT process through Wnt/β-catenin pathway to promote cancer metastasis[@b47][@b48]. Caveolin-1 is also an important regulator of cell polarity and directional movement[@b49]. The decreases in caveolin-1 expression follows classically described cellular changes associated with MET (including changes in cell morphology and expression of the E-cadherins and fibronectin)[@b50]. Our studies show that metapristone inhibits cell growth, and reverses EMT in conjunction with the activation of E-cadherin, and the inactivation of β-catenin and Caveolin-1 in MDA-MB-231 cells, implying that the MET potential of metapristone maybe related with Wnt signaling pathway.

In conclusion, our data show that metapristone inhibits migration, adhesion, and invasion abilities of the breast cancer cells. The pharmacoproteomic study reveals that metapristone intervenes EMT-related signaling pathways, such as TGF-β and Wnt signaling pathways, in conjunction with the activation of E-cadherin and glutaredoxin and inactivation of vimentin, TGFβ RI/RII, Smad2/3, RhoA, β-catenin and Caveolin-1 ([Fig. 6](#f6){ref-type="fig"}). These findings imply that the application of metapristone is a possible new method to control EMT, which contributes to metastatic processes in breast cancer. Our results suggest that knowledge of the putative pharmacoproteomic mechanisms will promote better use of existing drugs and facilitate the conception of new therapies and new drug development.

Materials and Methods
=====================

Cell culture, antibodies and reagents
-------------------------------------

MDA-MB-231 human breast cancer cells were purchased from American Type Culture Collection (ATCC, Manassas, VA) and maintained in ATCC-formulated Leibovitz's L-15 Medium (Catalog No. 30-2008). Cells were supplemented with heat inactivated fetal bovine serum to a final concentration of 10%, and incubated at 37 °C in a free gas exchange with atmospheric air. Mouse monoclonal anti-vimentin (ab8978), -E-cadherin (ab1416), -β-actin antibodies (ab6276), goat anti-rabbit (ab150077) and goat anti-mouse (ab150115) antibodies were all obtained from Abcam Corporation.

*In vitro* cytotoxicity studies
-------------------------------

The cytotoxicity of metapristone was investigated by the MTT assayas described previously by this lab[@b51][@b52]. Briefly, MDA-MB-231 cells were seeded into 96-well plates at a density of 1 × 10^4^ cells/well, and then incubated at 37 °C in a humidified atmosphere with 100% air. After overnight incubation, the cells were treated with different concentrations of metapristone for 24 h. Culture medium was used as a blank control. Then, cells were incubation with the MTT solution (5 mg/ml) in the medium without phenol red and serum for another 4 h. The MTT-formazan formed by metabolically viable cells was dissolved in 150 μl of dimethyl sulfoxide (DMSO). Cell viability was determined by detecting the absorbance at 565 nm using an infinite M200 Pro microplate reader (Tecan, Switzerland). The absorbance of untreated cells was considered as 100%. Each sample was assayed in triplicate in three independent experiments.

Wound healing assay
-------------------

Migration of MDA-MB-231 cells was investigated in the *in vitro* wound-healing assay as described previously by this lab[@b3][@b51]. The MDA-MB-231 cells were seeded in 6-well plate; once confluent, 10 μg/ml mitomycin C was added. The scratch wound was generated in the surface of the plate using a pipette tip, followed by extensive washing with serum-free medium to remove cell debris. DMSO (final concentration: 0.1%) as vehicle control was added after wounding. Cells were then cultured and allowed to migrate into the wound area for up to 24 h at 37 °C. At indicated time points, motility was quantified by measuring the average extent of wound closure. Each well was counted under a light microscope (Zeiss, Germany) at a magnification of 10 × and then photographed.

Cell invasion assay
-------------------

Cell invasion assay was performed using 24-well transwells (Costar, Coring Incorporated, USA), which allows cells to migrate through a polycarbonate membrane with 8-μm pore size as we described previously[@b52][@b53]. Briefly, in transwell cell culture chambers, filters of 8 mm pore size were coated with Matrigel on the upper surface. MDA-MB-231 cells were resuspended with reduced serum L-15 medium and seeded 5 × 10^4^ per well on the upper chamber of the transwell apparatus. Invasion assay was performed in the presence of 0, 10, 50, 75 μM of metapristone. DMSO (final concentration: 0.1%) was used as vehicle control. After 24 h incubation, the cells on the inner layer were softly removed with a cotton swab. Then, the adherent cells on undersurface of the insert were fixed in methanol and stained with 0.1% crystal violet for 20 min. The filters were washed with PBS and images were taken by a light microscope (Zeiss, Germany) at × 200 magnification. Five fields were counted per filter in each group and the experiment was conducted in triplicate.

Cell adhesion assay
-------------------

The adhesion assay of MDA-MB-231 cells to the HUVECs was assessed according to the method described previously by this lab with minor modifications[@b3][@b52]. Briefly, Human umbilical vein endothelial cells (HUVECs) were isolated and utilized between passages 2 and 5, and grown to confluence in 24-well culture plates. Then, TNF-α (final concentration: 10 ng/ml) was used to activate HUVECs for 4 hours. Rhodamine 123-labled MDA-MB-231 cells were co-cultured with the HUVEC monlayers in each well, followed by treatment with metapristone for 1 hour. DMSO (0.1%) was used as the vehicle control. The nonadherent cells were removed from the plate by careful three-time washings with PBS, and the MDA-MB-231 cells bound to the HUVECs were measured by a fluorescence microscope (Zeiss, Germany). Then, ten visual fields for each well were selected randomly and taken pictures. Mean inhibition of adhesion for 10 visual fields was calculated by using the equation: % of control adhesion = \[the number of adhered cells in treated group/the number of adhered cells in the control group\] × 100%.

Protein preparation and iTRAQ labeling
--------------------------------------

MDA-MB-231 cells were cultured and treated with 50 μM metapristone. Treated and untreated cells were suspended in the Lysis buffer (7 M Urea, 2 M Thiourea, 4% CHAPS, 40 mM Tris-HCl, pH8.5, 1 mM PMSF, 2 mM EDTA) and sonicated in ice. The proteins were reduced with 10 mM DTT (final concentration) at 56°C for 1 h and then alkylated by 55 mM IAM (final concentration) in the darkroom for 1 h. The reduced and alkylated protein mixtures were precipitated by adding 4 × volume of chilled acetone at −20 °C overnight. After centrifugation at 4 °C, 30000 g, the pellet was dissolved in 0.5 M TEAB (Applied Biosystems, Milan, Italy) and sonicated in ice. After centrifuging at 30000 g at 4°C, an aliquot of the supernatant was taken and protein concentration was determined using the Bradford method. Then, total protein (100 μg) of each sample was digested with Trypsin Gold (Promega, Madison, WI, USA) with the ratio of protein: trypsin = 30:1 at 37°C for 16 hours. After trypsin digestion, peptides were dried by vacuum centrifugation, reconstituted in 0.5 M TEAB, and processed according to the manufacture's protocol for 8-plex iTRAQ reagent (Applied Biosystems, Foster City,CA). The labeled peptide mixtures were pooled and dried by vacuum centrifugation, and then fractionated using Poly SULFOETHYL ATM SCX column (200 × 4.6 mm, 5 μm particle size, 200 A° pore size) by HPLC system (Shimadzu, Japan) at flow rate 1.0 ml min-1. The eluted peptides were pooled into 20 fractions, desalted with a Strata × C 18 column, concentrated to dryness using vacuum centrifuge and then reconstituted in 0.1% formic acid for LC-MS/MS analysis.

LC-ESI-MS/MS analysis based on Q EXACTIVE
-----------------------------------------

The mass spectroscopy analysis was performed using a tandem mass spectrometry (MS/MS) in an Q EXACTIVE (Thermo Fisher Scientific, San Jose, CA) coupled online to the HPLC as described before[@b54][@b55]. Peptides were selected for MS/MS using high-energy collision dissociation (HCD) operating mode with a normalized collision energy setting of 27.0; ion fragments were detected in the Orbitrap at a resolution of 17500. A data-dependent procedure that alternated between one MS scan followed by 15 MS/MS scan with a following Dynamic Exclusion duration of 15s. Proteins identification was performed by using Mascot search engine (Matrix Science, London, UK; version 2.3.02). For protein quantitation, it was required that a protein contains at least two unique peptides. The quantitative protein ratios were weighted and normalized by the median ratio in Mascot. We only used ratios with *p*-values \< 0.05, and only fold changes of \>1.5 were considered as significant.

Proteomic data analysis
-----------------------

Functional annotations of the proteins were conducted using Blast2GO program against the non-redundant protein database (NR; NCBI). The keg database ([http:www.genome.jp/keg/](http://www.genome.jp/keg/)), the COG database (<http://www.ncbi.nlm.nih.gov/COG/>), and GO (Gene Ontology) analyses (<http://www.geneontology.org>) were used to classify and group these identified proteins according to the methods reported in early literature[@b15][@b56].

Western blot analysis
---------------------

Cell lysates were collected using radio immunoprecipitation (RIPA) lysis buffer, supplemented with HALT protease and phosphatase inhibitor cocktail (Thermo Scientific), and immunodetection of electrophoresis-resolved proteins was performed using standard protocols. The E-Cadherin, vimentin, Smad2, pSmad2, β-catenin, and β-actin antibodies were from Abcam. Immunodetection was accomplished using enhanced chemiluminescence, and data were acquired with a quantitative digital imaging system (Quantity One, Bio-Rad) allowing it to check for saturation. Overall emitted photons were quantified for each band, particularly for homogeneously the loading controls.

Immunofluorescence staining and high-content confocal imaging
-------------------------------------------------------------

MDA-MB-231 cells were cultured on a 35 mm cell culture dish (NEST, GBD-35-20) to 50% confluence at least 2 days before carrying out the immunofluorescence assay. Cells (with or without metapristone-treatment) were first washed by phosphate buffer 3 times and then fixed by 4% paraformaldehyde for 30 minutes. One milliliter of 0.1% Triton-X-100 was subsequently added to culture cells for ten minutes to increase cell permeability. Cells were blocked for 30 minutes at room temperature with 10% goat serum followed by culturing with primary antibodies, mouse monoclonal anti-vimentin antibody and E-cadherin for 1 h at room temperature. Then cells were added with secondary antibodies, Goat Anti-Mouse IgG-FITC antibody (Boster, BA1101) and Goat Anti-Rabbit IgG-CY3 antibody (Boster, BA1032) respectively, and cultured in the dark for 1 h at room temperature. Phosphate buffer was used to wash cells for at least three times between every two contiguous steps. Confocal analysis was performed on a Leica-TCS-SP8 confocal microscope and the images were taken under the same parameter configuration.

Statistical analysis
--------------------

All data were analyzed using SASS software and expressed as the mean ± SD or SE. Statistical comparisons between different groups were performed using Student *t*-test. A *P* value of \<0.05 was considered to be statistically significant.
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![Cellular pharmacology analysis of metapristone.\
(**A**) *in vitro* activity of metapristone against MDA-MB-231 cell line. (**B**) dose-dependent inhibition by metapristone on cell migration. (**C**) inhibition by metapristone of MDA-MB-231 cells adhesion to HUVECs. Representative microscopic observation of the inhibition by metapristone at 0, 10, 50, and 75 μM. DMSO (0.1%) was used as vehicle control (average of 10 independent microscope fields for each of 3 independent experiments). (**D**) a Corning transwell system was used to assay cell invasion as described in methods. The amount of MDA-MB-231 cells invading through polycarbonate membranes was counted by microscopic observation (10×). Each experiment was carried out at least three times. \*\**P* \< 0.01.](srep22388-f1){#f1}

![Workflow used to study differential expressed proteins in MDA-MB-231 cells after metapristone treatment using iTRAQ technology.](srep22388-f2){#f2}

![Categorization of all differential expressed proteins by GO analysis.\
(**A**) cellular component. (**B**) biological process. C,molecular function (*P* \< 0.05).](srep22388-f3){#f3}

![Functional category coverage of the proteins identified.](srep22388-f4){#f4}

![The effect of metapristone on cell morphology and EMT markers in MDA-MB-231 cells.\
(**A**) morphological changes were observed by phase-contrast microscopy. (**B**,**C**) the expression of vimentin E-cadherin, β-catenin, Smad2, and pSmad2 in MDA-MB-231 cells treated with or without metapristone (50 μM) was assessed by immunoblotting analysis. (**D**) confocal microscope images of vimentin immunostained with goat anti-rabbit IgG-CY3 antibody (green) and E-cadherin immunostained with goat anti-mouse IgG-FITC antibody (red) in MDA-MB-231 cells untreated or treated metapristone (50 μM).](srep22388-f5){#f5}

![The schematic representation represents the MET potential of metapristone in MDA-MB-231 cells.\
Metapristone inhibits EMT by regulating TGF-β or Wnt signaling pathways. Metapristone inhibits EMT through Smad or non-Smad pathways involved in TGF-β signaling pathway, which results in suppression of mesenchymal and up-regulation of epithelial marker expression. Metapristone depressed EMT through regulating Wnt signaling pathway mediated by β-catenin and caveolin.](srep22388-f6){#f6}

###### Annotation of up-regulated proteins after metapristone treatment in MDA-MB-231 cells.

  No.    Score   % Cov   Accession number  Name                                                                                       Peptides   regulation (fold change)[a](#t1-fn1){ref-type="fn"}
  ----- ------- ------- ------------------ ----------------------------------------------------------------------------------------- ---------- -----------------------------------------------------
  1       226    17.3         D9HTE9       Plasma membrane citrate carrier                                                               5                             1.707\*
  2       503    14.5         P31040       Succinate dehydrogenase \[ubiquinone\] flavoprotein subunit, mitochondrial                    8                             3.644\*
  3       308    39.9         P62280       40S ribosomal protein S11                                                                     7                             1.709\*
  4       115    19.2         Q0QEY7       Succinate dehydrogenase complex subunit B                                                     4                             3.776\*
  5       474    27.8         P13073       Cytochrome c oxidase subunit 4 isoform 1, mitochondrial                                       5                             1.671\*
  6       267     30          Q53EW8       Thiosulfate sulfurtransferase variant                                                         7                             3.181\*
  7       488    30.3         E9PH29       Thioredoxin-dependent peroxide reductase, mitochondrial                                       6                             1.538\*
  8       446    20.7         A2A274       Aconitate hydratase, mitochondrial                                                            13                            1.528\*
  9       266    24.1         Q5QNZ2       ATP synthase F(0) complex subunit B1, mitochondrial                                           5                             1.681\*
  10      388    26.7         Q59FZ8       Nebulette non-muscle isoform variant                                                          9                             1.591\*
  11      302    14.5         A6NN80       Annexin                                                                                       10                            2.861\*
  12      410    50.3         O75947       ATP synthase subunit d, mitochondrial                                                         7                             3.498\*
  13     1130    34.2         Q59GB4       Dihydropyrimidinase-like 2 variant                                                            15                            1.781\*
  14      947    30.7        Q06210-2      Isoform 2 of Glutamine---fructose-6-phosphate aminotransferase \[isomerizing\] 1              16                           4.479\*\*
  15      212    16.1         G3V325       Pentatricopeptide repeat-containing protein 1, mitochondrial                                  4                             2.441\*
  16     2168    59.3         P00338       L-lactate dehydrogenase A chain                                                               17                            2.417\*
  17      135    15.3         B7Z792       cDNA FLJ53932                                                                                 5                             1.713\*
  18      518    16.9         D3DUJ0       AFG3 ATPase family gene 3-like 2, isoform CRA_a                                               11                            1.981\*
  19      388    63.2         E9PN17       ATP synthase subunit g, mitochondrial                                                         4                             1.709\*
  20      202    25.1         Q5HYK3       2-methoxy-6-polyprenyl-1,4-benzoquinol methylase, mitochondrial                               4                             2.408\*
  21      671    45.4        P15559-2      Isoform 2 of NAD(P)H dehydrogenase \[quinone\] 1                                              9                             3.405\*
  22      146    17.5         Q8N4T8       Carbonyl reductase family member 4                                                            4                            5.404\*\*
  23      474    29.8         P62277       40S ribosomal protein S13                                                                     5                             2.403\*
  24      189    23.7         B2RDE0       cDNA, FLJ96567                                                                                8                            6.402\*\*
  25     1329    48.2         Q53FB6       Mitochondrial aldehyde dehydrogenase 2 variant                                                19                           5.389\*\*
  26      530    26.7         Q53FC3       Programmed cell death 6 variant                                                               5                             2.312\*
  27      161    20.9         Q9UK22       F-box only protein 2                                                                          5                             1.975\*
  28      148    22.6         P18827       Syndecan-1                                                                                    5                             4.562\*
  29      458    35.2         Q5T9B7       Adenylate kinase isoenzyme 1                                                                  6                             2.334\*
  30      237    17.5         B3KMV8       cDNA FLJ12766 fis, clone NT2RP2001520                                                         6                             3.366\*
  31      252    28.7         I3L1P8       Mitochondrial 2-oxoglutarate/malate carrier protein (Fragment)                                6                             2.364\*
  32      167    52.2         P56385       ATP synthase subunit e, mitochondrial                                                         4                             4.361\*
  33      216    24.1         B3KTJ1       cDNA FLJ38349 fis, clone FEBRA1000057                                                         6                             5.353\*
  34      259    22.4         Q5M7Z1       RAD23 homolog A (S. cerevisiae)                                                               4                             3.351\*
  35      177    30.2         Q9H479       Fructosamine-3-kinase                                                                         4                             2.342\*
  36      160    19.5         B4DNW0       Aminoacylase-1                                                                                9                             2.921\*
  37      775     23          O60832       H/ACA ribonucleoprotein complex subunit                                                       10                           3.339\*\*
  38      104    36.5         Q9NRV9       Heme-binding protein 1                                                                        5                             1.759\*
  39      194    43.4         P35754       Glutaredoxin-1                                                                                4                             4.368\*
  40      362     22          Q96I99       Succinyl-CoA ligase \[GDP-forming\] subunit beta, mitochondrial                               9                             1.837\*
  41      156    24.6         F5GZW3       Rho GTPase-activating protein 4                                                               4                             1.536\*
  42      144    33.8         A8KA74       cDNA FLJ76065                                                                                 4                             1.625\*
  43      434    24.4         B4E2Z8       cDNA FLJ61206                                                                                 8                             1.734\*
  44      904     37         P11177-2      Isoform 2 of Pyruvate dehydrogenase E1 component subunit beta, mitochondrial                  10                            2.333\*
  45      699    31.6         P00966       Argininosuccinate synthase                                                                    13                            2.302\*
  46      109    22.6         Q5SRD1       Putative mitochondrial import inner membrane translocase subunit Tim23B                       4                             2.133\*
  47      969    25.4         Q9NSE4       Isoleucine---tRNA ligase, mitochondrial                                                       22                           6.329\*\*
  48      254     15         Q8N0 × 4      Citrate lyase subunit beta-like protein, mitochondrial                                        4                             3.327\*
  49      222    15.2         Q14376       UDP-glucose 4-epimerase                                                                       4                            7.325\*\*
  50      225    36.7         Q86WA8       Lon protease homolog 2, peroxisomal                                                           4                             5.324\*
  51      128    42.1        P43155-2      Isoform 2 of Carnitine O-acetyltransferase                                                    5                             1.724\*
  52      414    19.6         D7PBN3       ESRP1/RAF1 fusion protein                                                                     13                            2.324\*
  53     2112    50.5         Q59EI9       ADP,ATP carrier protein, liver isoform T2 variant                                             16                           7.32\*\*
  54      381    29.3         D3XNU5       E-cadherin 1                                                                                  6                            7.319\*\*
  55      398    22.8         D3DVA5       Rho/rac guanine nucleotide exchange factor (GEF) 2, isoform CRA_a                             12                            1.619\*
  56      346    20.8         B4E290       cDNA FLJ50039                                                                                 10                           8.318\*\*
  57     1299    50.5         P12429       Annexin A3                                                                                    15                            2.322\*
  58      379    22.4         B7Z3K9       Fructose-bisphosphate aldolase                                                                8                             2.315\*
  59      151    19.9        Q9H974-2      Isoform 2 of Queuine tRNA-ribosyltransferase subunit QTRTD1                                   4                             1.751\*
  60      556     23          B4DFP1       cDNA FLJ51818                                                                                 12                            1.815\*
  61      679     45          P84085       ADP-ribosylation factor 5                                                                     8                             1.663\*
  62      317    18.8        P80303-2      Isoform 2 of Nucleobindin-2                                                                   7                             2.306\*
  63      402    16.5         Q8NE62       Choline dehydrogenase, mitochondrial                                                          9                             1.996\*
  64     1016    32.6         Q13011       Delta(3, 5)-Delta(2, 4)-dienoyl-CoA isomerase, mitochondrial                                  10                            1.703\*
  65      149    36.8        Q7Z4G4-2      Isoform 2 of tRNA (guanine(10)-N2)-methyltransferase homolog                                  5                             2.302\*
  66      227    21.2         B4DG80       LIM and cysteine-rich domains protein 1                                                       5                             3.271\*
  67      122    26.3         O00178       GTP-binding protein 1                                                                         4                             2.111\*
  68      196    24.8         H3BNX8       Cytochrome c oxidase subunit 5A, mitochondrial                                                5                             3.022\*
  69      264    31.6         O95865       N(G), N(G)-dimethylarginine dimethylaminohydrolase 2                                          7                             2.395\*
  70      286    41.8        P36969-2      Isoform Cytoplasmic of Phospholipid hydroperoxide glutathione peroxidase, mitochondrial       7                             1.795\*
  71      238    21.9         B3KTM6       Ribosomal protein L5, isoform CRA_b                                                           5                             1.694\*
  72      891    48.9         P18085       ADP-ribosylation factor 4                                                                     8                             1.742\*
  73      105     18          Q96CF2       Charged multivesicular body protein 4c                                                        4                             1.562\*
  74      714    20.5        Q6XQN6-3      Isoform 3 of Nicotinate phosphoribosyltransferase                                             4                             2.291\*
  75      419    72.1         Q9HCY8       Protein S100-A14                                                                              6                             1.287\*
  76      416    22.7         Q8IYS1       Peptidase M20 domain-containing protein 2                                                     9                             2.286\*
  77     1692    35.4         Q59EK6       TNF receptor-associated protein 1 variant                                                     21                            1.986\*
  78      192    16.7         B3KQQ0       cDNA PSEC0007 fis, clone NT2RM1000634                                                         8                             1.784\*
  79      322    27.7         B4DP80       cDNA FLJ56357                                                                                 6                             2.283\*
  80      270    14.4         B4DUF1       cDNA FLJ59760                                                                                 8                             2.252\*
  81      519    28.8         P31930       Cytochrome b-c1 complex subunit 1, mitochondrial                                              10                            3.281\*
  82      278    33.5         B7Z4B7       cDNA FLJ52561                                                                                 7                             2.218\*
  83     1591    37.3         K7EKE6       Lon protease homolog, mitochondrial                                                           25                            3.278\*
  84      345     25          P04040       Catalase                                                                                      11                            3.215\*
  85     1420    58.6        P30044-2      Isoform Cytoplasmic + peroxisomal of Peroxiredoxin-5, mitochondrial                           7                             2.275\*
  86      571    44.9         B4DNR3       cDNA FLJ52710                                                                                 6                            8.214\*\*
  87      213    46.8         B4DRT2       28S ribosomal protein S27, mitochondrial                                                      4                            7.212\*\*
  88      412    24.4         Q6NVY1       3-hydroxyisobutyryl-CoA hydrolase, mitochondrial                                              9                            6.274\*\*
  89      636     47          M0R0F0       40S ribosomal protein S5 (Fragment)                                                           10                          11.271\*\*
  90      254    45.4         P61081       NEDD8-conjugating enzyme Ubc12                                                                8                            6.269\*\*
  91      524    23.1         P17858       6-phosphofructokinase, liver type                                                             14                           7.368\*\*
  92      146    11.2         Q53H22       Amidophosphoribosyltransferase                                                                5                             2.068\*
  93      152    19.1         P46781       40S ribosomal protein S9                                                                      4                             1.968\*
  94      227    25.6         Q9NWV4       UPF0587 protein C1orf123                                                                      5                             1.266\*
  95      159    19.4         B3KRI2       NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 7, mitochondrial                        4                             3.214\*
  96      646    21.6         B2R9S4       cDNA, FLJ94534                                                                                6                             1.963\*
  97      296    18.4         B2R6S5       Cytidylate kinase, isoform CRA_a                                                              4                           10.262\*\*
  98      576    16.1        Q9UJS0-2      Isoform 2 of Calcium-binding mitochondrial carrier protein Aralar2                            8                            8.261\*\*
  99      269    39.5         O75368       SH3 domain-binding glutamic acid-rich-like protein                                            4                            7.259\*\*
  100     522    45.2         O75223       Gamma-glutamylcyclotransferase                                                                8                             6.229\*
  101     168    24.7        B2R9 × 3      cDNA, FLJ94599                                                                                10                            5.257\*
  102    2592    45.5         Q6NVC0       SLC25A5 protein (Fragment) OS = Homo sapiens                                                  16                            3.255\*
  103     319    22.5         Q9BQ69       O-acetyl-ADP-ribose deacetylase MACROD1                                                       6                             3.154\*
  104     179    14.8         Q6V9R7       Solute carrier family 25 member 19                                                            4                             1.752\*
  105     108    23.6         Q8IW45       ATP-dependent (S)-NAD(P)H-hydrate dehydratase                                                 5                             1.922\*
  106     878    32.4         P35908       Keratin, type II cytoskeletal 2 epidermal                                                     18                            3.251\*
  107     953    37.6        P49419-2      Isoform 2 of Alpha-aminoadipic semialdehyde dehydrogenase                                     16                           5.338\*\*
  108     751    30.1         P07384       Calpain-1 catalytic subunit                                                                   19                            7.247\*
  109     564     62          O95336       6-phosphogluconolactonase                                                                     11                          11.246\*\*
  110     176    14.1        Q9H9T3-2      Isoform 2 of Elongator complex protein 3                                                      6                             5.245\*
  111    2382    35.4         Q53F91       Villin 1 variant                                                                              27                           3.245\*\*
  112     247    31.4         B4DP27       cDNA FLJ52153                                                                                 5                             2.242\*
  113     365    25.9         Q9NUQ9       Protein FAM49B                                                                                7                             3.551\*
  114     268    35.6         E7EW20       Unconventional myosin-VI                                                                      9                            7.241\*\*
  115    4889    43.5        B7Z2 × 9      Gamma-enolase                                                                                 13                            5.244\*
  116     494    15.2         P10253       Lysosomal alpha-glucosidase                                                                   10                            3.379\*
  117     167    20.2         P15328       Folate receptor alphas                                                                        4                             2.238\*
  118     166    28.4         Q13315       Serine-protein kinase ATM                                                                     6                             5.238\*
  119     232    20.2         B3KM98       cDNA FLJ10556 fis, clone NT2RP2002479                                                         6                             6.238\*
  120     267    29.7         Q02338       D-beta-hydroxybutyrate dehydrogenase, mitochondrial                                           7                             4.235\*
  121     673    44.2         B7Z6B8       2,4-dienoyl-CoA reductase, mitochondrial                                                      11                           9.215\*\*
  122     114    20.9         B4DQ51       Short/branched chain-specific acyl-CoA dehydrogenase, mitochondrial                           4                            8.234\*\*
  123    2746    43.8         P40939       Trifunctional enzyme subunit alpha, mitochondrial                                             31                           7.212\*\*
  124     437    28.9         P31937       3-hydroxyisobutyrate dehydrogenase, mitochondrial                                             6                             5.212\*
  125     214    33.5         B3KTS4       cDNA FLJ38665 fis, clone HLUNG2003378                                                         8                             4.222\*
  126    3670    56.3         P06899       Histone H2B type 1-J                                                                          8                           10.231\*\*
  127    5762    59.3         Q13885       Tubulin beta-2A chain                                                                         21                            1.831\*
  128     647    27.9         B2RAH7       cDNA, FLJ94921                                                                                16                            1.529\*
  129     443    17.5         O95202       LETM1 and EF-hand domain-containing protein 1, mitochondrial                                  11                            2.229\*
  130     766    24.7         Q0VGA5       SARS protein s                                                                                10                            1.729\*
  131     407    33.7        Q9Y305-2      Isoform 2 of Acyl-coenzyme A thioesterase 9, mitochondrial                                    12                            1.855\*
  132     317    35.1        P63000-2      Isoform B of Ras-related C3 botulinum toxin substrate 1                                       7                             2.277\*
  133     103    21.5         Q9C0C9       Ubiquitin-conjugating enzyme E2 O                                                             5                            6.217\*\*
  134     114    14.1         P04792       Heat shock protein beta-1                                                                     4                             5.246\*
  135     248    15.7         Q9UBF2       Coatomer subunit gamma-2                                                                      4                             6.213\*
  136     356    63.9         P07741       Adenine phosphoribosyltransferase                                                             8                            7.273\*\*
  137     260    14.7        Q8TE67-2      Isoform 2 of Epidermal growth factor receptor kinase substrate 8-like protein 3               8                             2.222\*
  138    2952     49          P09211       Glutathione S-transferase P                                                                   9                             1.825\*
  139     343    43.8         Q8TCD5       5\~(3\~)-deoxyribonucleotidase, cytosolic type                                                6                             2.261\*
  140     234    26.9         Q8NCF7       cDNA FLJ90278 fis, clone NT2RP1000325                                                         10                            2.254\*
  141     739    45.2         P14550       Alcohol dehydrogenase \[NADP(+)\]                                                             13                            1.722\*
  142     138     19          B2RCC2       cDNA, FLJ95978                                                                                5                             1.998\*
  143     235    16.4         Q9BRQ8       Apoptosis-inducing factor 2                                                                   6                            9.217\*\*
  144     267     39          P30046       D-dopachrome decarboxylase                                                                    4                             3.217\*
  145     144    16.4         B4DRN7       C2 domain-containing protein 5                                                                5                            8.216\*\*
  146    1762    51.4         Q6LES2       Annexin (Fragment)                                                                            15                           8.113\*\*
  147     383    21.8         Q5JNW7       Proteasome subunit beta type-8                                                                4                           12.212\*\*
  148     126    20.9         Q96GD0       Pyridoxal phosphate phosphatase                                                               4                             7.202\*
  149     516    45.7         Q9NQR4       Omega-amidase NIT2                                                                            11                           7.254\*\*
  150     278    16.6         B3KM97       cDNA FLJ10554 fis, clone NT2RP2002385                                                         5                             1.911\*
  151     427    25.1         J3QQX3       NADPH:adrenodoxin oxidoreductase, mitochondrial                                               8                             1.721\*
  152     184    19.1         P47929       Galectin-7                                                                                    4                            7.209\*\*
  153     125    22.9         Q6PJ77       BTF3L4 protein (Fragment)                                                                     4                            6.209\*\*
  154     228    17.3         R4GMU1       GDH/6PGL endoplasmic bifunctional protein                                                     9                            5.248\*\*
  155     326    32.7         B2R7T6       cDNA, FLJ93596                                                                                12                           7.217\*\*
  156     175    21.2         Q9BUL8       Programmed cell death protein 10                                                              5                             3.252\*
  157     264    19.6         B2R673       cDNA, FLJ92818                                                                                9                             1.884\*
  158     341    34.1         G8JLB3       tRNA pseudouridine synthase (Fragment)                                                        11                            1.653\*
  159    1093     26          F8W930       Insulin-like growth factor 2 mRNA-binding protein 2                                           13                           8.224\*\*
  160     169     16          Q15031       Probable leucine---tRNA ligase, mitochondrial                                                 5                             5.263\*
  161    2146    44.7         O43175       D-3-phosphoglycerate dehydrogenase                                                            20                            5.211\*
  162     516    22.2         B4E0B1       cDNA FLJ52100                                                                                 4                             3.202\*
  163     151    20.3         B4DKL4       Lipolysis-stimulated lipoprotein receptor                                                     6                             2.328\*

^a^Regulations (fold-changes) of differentially expressed proteins in MDA-MB-231 cells (metapristone-treatment versus control). \**P* \< 0.05; \*\**P* \< 0.01.

###### Annotation of down-regulated proteins after metapristone treatment in MDA-MB-231 cells.

  No.    Score   \% Cov   Accession number  Name                                                                     Peptides   regulation (fold change)[a](#t2-fn1){ref-type="fn"}
  ----- ------- -------- ------------------ ----------------------------------------------------------------------- ---------- -----------------------------------------------------
  1       701     35.3         A8K9B9       cDNA FLJ77391                                                               17                            0.331\*
  2       286     31.4         B3KQF5       cDNA FLJ90381 fis, clone NT2RP2005035                                       8                             0.511\*
  3       451     20.1         Q9H089       Large subunit GTPase 1 homolog                                              11                            0.621\*
  4       167     22.4         A7UJ17       DnaJ                                                                        4                             0.431\*
  5       178     18.3         Q53HF3       Galactosidase, alpha variant                                                4                             0.383\*
  6       165     14.7        Q9BTM9-2      Isoform 2 of Ubiquitin-related modifier 1                                   4                             0.501\*
  7       263     22.7         Q8NAF0       Zinc finger protein 579                                                     4                             0.528\*
  8       221     18.1         Q9BPX3       Condensin complex subunit 3                                                 10                            0.438\*
  9       122     21.3         J3QTQ0       Dystonin                                                                    8                             0.607\*
  10      175     16.2         B4DQM4       GPN-loop GTPase 1                                                           4                             0.527\*
  11      437      27          J3KQA0       Synaptotagmin I, isoform CRA_b                                              10                            0.694\*
  12      119     15.4         B2R728       cDNA, FLJ9325                                                               4                             0.603\*
  13      133     23.1        Q13308-2      Isoform 2 of Inactive tyrosine-protein kinase 7                             6                            0.324\*\*
  14     2854      46         A8K2 × 8      cDNA FLJ78433                                                               25                            0.523\*
  15      226     12.8         Q9ULX6       A-kinase anchor protein 8-like                                              6                             0.612\*
  16      704     30.3         Q6FHK7       PSME3 protein                                                               7                             0.521\*
  17      479     25.4         A8K878       cDNA FLJ77177                                                               4                            0.282\*\*
  18      612      36          P84022       Smad3                                                                       5                            0.233\*\*
  19      532     20.1         M0QY97       Zinc finger CCCH domain-containing protein 4                                13                            0.619\*
  20      316     22.2         Q7Z417       Nuclear fragile X mental retardation-interacting protein 2                  7                             0.518\*
  21      117     25.4         Q9UHN6       Transmembrane protein 2                                                     5                            0.317\*\*
  22      274     14.6         B4DNN4       Ribonucleoside-diphosphate reductase                                        9                             0.516\*
  23      172     21.9         Q12846       Syntaxin-4                                                                  5                             0.415\*
  24      139     25.8         H0Y5K5       Endoplasmic reticulum-Golgi intermediate compartment protein 3              4                            0.414\*\*
  25      215     40.1         B4DGU4       Catenin beta-1                                                              5                            0.446\*\*
  26      287     32.7         K7EPB2       cAMP-dependent protein kinase type I-alpha regulatory subunit               9                            0.332\*\*
  27      131     16.1         B2WTI3       Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6               4                             0.632\*
  28      260      15          B3KN49       cDNA FLJ13562 fis, clone PLACE1008080                                       5                            0.211\*\*
  29      269     17.7         B3KSG9       cDNA FLJ36188 fis, clone TESTI2027179                                       5                            0.441\*\*
  30      519     27.1         P46013       Antigen KI-67                                                               20                           0.281\*\*
  31      219     32.9         Q96A35       39S ribosomal protein L24, mitochondrial                                    6                            0.181\*\*
  32      445     21.6         B7Z591       Transmembrane and coiled-coil domains 1, isoform CRA_a                      4                            0.409\*\*
  33      457     17.9        Q9NYF8-2      Isoform 2 of Bcl-2-associated transcription factor 1                        11                           0.338\*\*
  34      222     25.8         Q9UNK0       Syntaxin-8                                                                  6                             0.467\*
  35      247     21.5         Q9BYK8       Helicase with zinc finger domain 2                                          4                             0.607\*
  36      156     19.7         Q6LEU0       STX12 protein                                                               4                             0.557\*
  37      164     29.1         B2R6J0       Homo sapiens SRY (sex determining region Y)-box 2 (SOX2)                    4                            0.204\*\*
  38      394     16.7        Q92896-2      Isoform 2 of Golgi apparatus protein 1                                      19                            0.304\*
  39      226     15.8         B4DRG7       Condensin complex subunit                                                   10                            0.514\*
  40      161     21.4         Q9BXK1       Krueppel-like factor 16                                                     4                             0.353\*
  41      281     17.4         Q8NFC6       Biorientation of chromosomes in cell division protein 1-like 1              4                             0.409\*
  42      118     24.8         P17301       Integrin alpha-2                                                            5                            0.322\*\*
  43      457     22.9        Q15796-2      Smad2                                                                       6                            0.201\*\*
  44      845     36.8         P61586       Transforming protein RhoA                                                   6                             0.374\*
  45      124     15.7         Q15628       Tumor necrosis factor receptor type 1-associated DEATH domain protein       4                            0.26\*\*
  46      437     19.5         Q01650       Large neutral amino acids transporter small subunit 1                       4                             0.201\*
  47      718     22.9         Q86U75       Dihydropyrimidinase-like 2                                                  10                            0.244\*
  48      895     19.3         H3BUX2       Cytochrome b5 type B                                                        4                             0.508\*
  49      674     43.9         H0YKC5       Deoxyuridine 5\~-triphosphate nucleotidohydrolase, mitochondrial            7                             0.299\*
  50      355     27.2         P62906       60S ribosomal protein L10a                                                  5                             0.633\*
  51      287     14.5         B3KM90       cDNA FLJ10529 fis, clone NT2RP2000965                                       8                             0.672\*
  52      134     17.9         Q8NCC3       Group XV phospholipase A2                                                   4                             0.495\*
  53      148     19.8         Q3LIB1       Putative uncharacterized protein Nbla00445                                  8                             0.612\*
  54      163     20.4         O43752       Syntaxin-6                                                                  5                             0.679\*
  55     1445     53.8         P04083       Annexin A1                                                                  15                            0.586\*
  56      507     29.2         P20645       Cation-dependent mannose-6-phosphate receptor                               7                            0.385\*\*
  57      349     41.9         P60520       Gamma-aminobutyric acid receptor-associated protein-like 2                  6                            0.283\*\*
  58     1061     47.1         Q6FI35       Proliferating cell nuclear antigen                                          11                           0.381\*\*
  59      156     33.4         B2RMQ4       Cytoskeleton associated protein 2                                           4                             0.607\*
  60      192     16.5         G3V5T9       Cyclin-dependent kinase 2                                                   5                             0.633\*
  61      263     37.9         Q6IAA8       Ragulator complex protein LAMTOR1                                           4                             0.576\*
  62      150     18.1         B4DJI2       cDNA FLJ53342                                                               4                             0.624\*
  63      108      22          B2R7M1       cDNA, FLJ93507                                                              4                             0.376\*
  64      140     17.3         H0Y3T6       45 kDa calcium-binding protein                                              4                             0.558\*
  65      147     27.4         F8VX04       Sodium-coupled neutral amino acid transporter 1                             4                             0.471\*
  66     1103     54.2         B4DJP7       Small nuclear ribonucleoprotein Sm D3                                       5                            0.277\*\*
  67      731     26.1        O94925-3      Isoform 3 of Glutaminase kidney isoform, mitochondrial                      13                           0.167\*\*
  68      178     35.3         P51151       Ras-related protein Rab-9A                                                  5                            0.267\*\*
  69      197     20.7       P15529-16      Isoform 3 of Membrane cofactor protein                                      4                             0.566\*
  70      125     18.9        P46087-4      Isoform 4 of Putative ribosomal RNA methyltransferase NOP2                  6                            0.162\*\*
  71      268     23.6         D6W4Z6       HCG23833, isoform CRA_b                                                     4                             0.654\*
  72      271     27.9         B7ZM24       SLC12A2 protein                                                             9                            0.64\*\*
  73      583     42.1        P36897.1      TGF-beta receptor type-1                                                    4                            0.335\*\*
  74      321     20.2         P98172       Ephrin-B1                                                                   5                             0.539\*
  75      192     25.3         B7Z5A7       cDNA FLJ57557                                                               4                             0.454\*
  76      186     39.4         B4E324       cDNA FLJ60397                                                               4                             0.552\*
  77      200     15.1        Q9H5V8-2      Isoform 2 of CUB domain-containing protein 1                                10                            0.648\*
  78      249     18.6        Q96T88-2      Isoform 2 of E3 ubiquitin-protein ligase UHRF1                              6                            0.145\*\*
  79      241     35.9        B2R7 × 3      cDNA, FLJ93645                                                              4                            0.245\*\*
  80      191     22.6         P54709       Sodium/potassium-transporting ATPase subunit beta-3                         6                             0.544\*
  81      119      18          O14672       Disintegrin and metalloproteinase domain-containing protein 10              6                            0.342\*\*
  82      257      18          B3KXC3       Ferritin                                                                    5                             0.557\*
  83      236     51.1         K7EJT5       60S ribosomal protein L22                                                   6                             0.544\*
  84      278     14.9        B7Z4 × 6      cDNA FLJ51012, highly similar to Plasminogen activator inhibitor 1          5                            0.339\*\*
  85     1951     38.6         Q9NR30       Nucleolar RNA helicase 2                                                    25                            0.445\*
  86      175     15.4         B2RAK1       cDNA, FLJ94965                                                              11                            0.537\*
  87      209     26.9         B4DMR3       cDNA FLJ51896, highly similar to Glia-derived nexin                         8                            0.235\*\*
  88      332     18.6         Q53G91       Solute carrier family 16, member 3 variant (Fragment)                       4                             0.334\*
  89      130     16.3         Q5U8S2       Syntaxin 10                                                                 4                            0.233\*\*
  90      136     18.2         Q9UNE7       E3 ubiquitin-protein ligase CHIP                                            5                             0.402\*
  91      385     26.5         Q7Z4F3       Caveolin                                                                    4                             0.471\*
  92      130     18.2         A8KAQ6       cDNA FLJ76490                                                               4                             0.322\*
  93     2202     38.5         B4DMF5       Glutamate dehydrogenase                                                     16                           0.207\*\*
  94      143     22.7         B2R6P4       cDNA, FLJ93048                                                              4                            0.113\*\*
  95     1581     68.6         P51149       Ras-related protein Rab-7a                                                  13                           0.246\*\*
  96      257     15.9         H3BRB3       Kinesin-like protein KIF22                                                  4                             0.517\*
  97      277     18.2        P81605-2      Isoform 2 of Dermcidin                                                      4                             0.606\*
  98      263     19.1         Q8N353       TMEM106B protein                                                            5                             0.399\*
  99     1189     34.5         Q53G71       Calreticulin variant                                                        11                            0.601\*
  100     395     20.9         Q13217       DnaJ homolog subfamily C member 3                                           5                             0.374\*
  101     126     17.4         B2RE34       cDNA, FLJ96901                                                              4                             0.442\*
  102     174      26          Q53GY1       BCL2-associated athanogene 3 variant                                        4                             0.501\*
  103     200      38          Q9NQW6       Actin-binding protein anillin                                               8                             0.695\*
  104     110     27.9         A8K3S3       cDNA FLJ75664                                                               5                             0.326\*
  105     326     18.1         A8K201       cDNA FLJ75605                                                               4                             0.425\*
  106     115     17.9         A8K274       cDNA FLJ78227                                                               4                             0.689\*
  107     438     25.8        Q9NQ29-2      Isoform 2 of Putative RNA-binding protein Luc7-like 1                       8                             0.686\*
  108    20862    51.2        Q15149-4      Isoform 4 of Plectin                                                        20                            0.686\*
  109     164     27.5         O00161       Synaptosomal-associated protein 23                                          4                             0.68\*
  110     457     18.5         Q59EZ3       Insulin-like growth factor 2 receptor variant                               25                            0.678\*
  111     362      18          A8MXZ4       G-protein-coupled receptor family C group 5 member C                        5                             0.673\*
  112     682     14.9         B3KRY3       cDNA FLJ35079 fis, clone PLACE6005283                                       6                            0.398\*\*
  113     120     26.3         B4DN85       E3 ubiquitin-protein ligase                                                 4                             0.595\*
  114     108     10.8         O15269       Serine palmitoyltransferase 1                                               5                             0.67\*
  115     382     24.2         B4DL49       cDNA FLJ58073, moderately similar to Cathepsin B                            5                             0.67\*
  116     139      16          H0YDJ9       CD81 antigen                                                                4                             0.657\*
  117     522     32.4         B4DKJ4       cDNA FLJ57738                                                               4                            0.232\*\*
  118     149     25.2         B5BU32       Thymidine kinase                                                            5                             0.652\*
  119     122     33.8         O75976       Carboxypeptidase D                                                          4                             0.332\*
  120     618     19.3         P29317       Ephrin type-A receptor 2                                                    11                            0.651\*
  121     117     24.1         D6RAR4       Hepatocyte growth factor activator                                          4                             0.451\*
  122     198     32.6         G3V3D1       Epididymal secretory protein E1                                             6                             0.643\*
  123     286     30.7         C0JYY2       Apolipoprotein B                                                            4                             0.64\*
  124     114      29          F5H569       V-type proton ATPase 116 kDa subunit a isoform 1                            6                            0.276\*\*
  125     178     31.7         B4E1K0       Kinesin-like protein KIF23                                                  4                             0.633\*
  126     156     51.4         Q53HU8       vimentin                                                                    5                             0.413\*
  127     125     34.5         Q14118       Dystroglycan                                                                4                             0.614\*
  128     128     16.2         C1K3N4       Tumor necrosis factor receptor superfamily member 10a                       4                             0.592\*
  129     165     32.6        Q13501-2      Isoform 2 of Sequestosome-1                                                 4                             0.58\*
  130     290     26.8         F5GZY0       Amyloid-like protein 2                                                      4                             0.576\*
  131     410     26.2         B4DJQ8       cDNA FLJ5569                                                                8                            0.174\*\*
  132    1790     32.8         P11387       DNA topoisomerase 1                                                         26                           0.044\*\*
  133     186     17.3         B2R686       Trans-golgi network protein 2, isoform CRA_a                                4                             0.542\*
  134     191     30.7         H0Y8A7       NEDD4 family-interacting protein 2                                          4                            0.331\*\*
  135     112     27.7         P62266       40S ribosomal protein S23                                                   5                             0.53\*
  136     159     33.4         B3KMB6       cDNA FLJ10642 fis, clone NT2RP2005752                                       7                             0.53\*
  137     175      25          B4DSG5       cDNA FLJ56149                                                               5                             0.525\*
  138     893     24.8         Q71UA6       Neutral amino acid transporter                                              10                            0.499\*
  139     179     15.8         A8K6H9       cDNA FLJ75876                                                               5                             0.486\*
  140     198     28.6         Q9NRX5       Serine incorporator 1                                                       4                             0.442\*
  141     125     18.8         B4DIB1       cDNA FLJ55065                                                               5                             0.427\*
  142     137     17.3        P37173-2      Isoform 2 of TGF-beta receptor type-2                                       4                             0.349\*
  143     753     25.1         P55010       Eukaryotic translation initiation factor 5                                  9                             0.315\*
  144     121     35.7         P14174       Macrophage migration inhibitory factor                                      4                            0.299\*\*
  145     325     24.1         E7EQY1       Protein FAM136A                                                             5                             0.432\*
  146     124     19.6         Q9NY27       Serine/threonine-protein phosphatase 4 regulatory subunit 2                 4                             0.411\*
  147     900     24.4         P62306       Small nuclear ribonucleoprotein F                                           4                             0.558\*
  148     256     19.8         C9JEH3       Angio-associated migratory cell protein                                     7                            0.512\*\*

^a^Regulations (fold-changes) of differentially expressed proteins in MDA-MB-231 cells (metapristone-treatment versus control). \**P* \< 0.05; \*\**P* \< 0.01.

###### Pathway analysis of the DEPs obtained from the iTRAQ analysis.

  Pathway description                     Count   *P*-value
  -------------------------------------- ------- -----------
  Metabolic pathways                       81     5.21E-11
  RNA transport                            74     1.13E-10
  Endocytosis                              58     1.49E-10
  Oxidative phosphorylation                56     2.83E-09
  Apoptosis                                53     5.78E-09
  Focal adhesion                           48     1.18E-08
  MAPK signaling pathway                   36     5.62E-08
  Regulation of actin cytoskeleton         35     8.21E-08
  GnRH signaling pathway                   33     1.91E-07
  B cell receptor signaling pathway        31     2.05E-07
  Calcium signaling pathway                30     1.13E-06
  Chemokine signaling pathway              28     3.61E-06
  NF-kappa B signaling pathwy              27     4.13E-06
  Peroxisome                               27     1.70E-05
  T cell receptor signaling pathway        25     2.18E-05
  ErbB signaling pathway                   23     3.62E-05
  Neurotrophin signaling pathway           23     4.21E-05
  Toll-like receptor signaling pathway     23     4.36E-05
  Jak-STAT signaling pathway               23     6.99E-05
  Insulin signaling pathway                20     0.000134
  Notch signaling pathway                  21     0.000313
  ECM-receptor interaction                 19     0.000397
  mTOR signaling pathway                   19     0.000724
  p53 signaling pathway                    17     0.000797
  TGF-beta signaling pathway               17     0.000913
  VEGF signaling pathway                   16     0.001033
  PPAR signaling pathway                   15     0.001334
  Adherens junction                        13     0.001427
  Wnt signaling pathway                    12     0.003628
  Cell adhesion molecules (CAMs)           11     0.003316
  Drug metabolism-cytochrome P450           8     0.004733
  ABC transporters                          7     0.007124
  Regulation of autophagy                   6     0.008114

There were 249 pathways revealed. Among them, the following 33 signaling pathways were significant (*P* \< 0.01).

[^1]: These authors contributed equally to this work.
